Last reviewed · How we verify
NCT03649672: CaliRev
The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor
NA trial testing TOF Watch SX in Neuromuscular Blockade in 64 participants. Terminated before completion.
9 November 2021
Quick facts
| Lead sponsor | Christoph Czarnetzki |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 64 |
| Start date | 26 October 2018 |
| Primary completion | 9 November 2021 |
| Estimated completion | 9 November 2021 |
| Sites | 2 locations across Switzerland |
Drugs / interventions tested
- TOF Watch SX
Conditions studied
- Neuromuscular Blockade — all drugs for Neuromuscular Blockade →
Sponsor
Christoph Czarnetzki
Who can join
Adults 18 to 65, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neuromuscular blocking agents (NMBAs) are frequently used in anesthesia and quantitative monitoring of neuromuscular block is standard care. Normally the calibration of the neuromuscular monitor is done after anesthesia induction to avoid patient discomfort. Under certain circumstances there is no time for the calibration process. In the so-called rapid sequence induction (RSI) the neuromuscular blocking agent has to be injected immediately after the induction agent. As the neuromuscular monitor cannot be calibrated, precise neuromuscular monitoring is not possible, and this is of particular disadvantage, when high doses of non-depolarizing neuromuscular blockers are injected to fasten the onset of neuromuscular block. The primary objective is to validate the measurements of the TOF Watch SX® monitor calibrated in awake patients by comparing them with the measurements obtained with the TOF Watch SX® monitor calibrated after anesthesia induction (Gold standard). The secondary objective is to evaluate the tolerability of the awake calibration process of the TOF Watch SX® monitor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03649672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuromuscular Blockade
Currently open trials in the same condition.
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
- NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting
Other Christoph Czarnetzki trials
Trials by the same sponsor.
- NCT05261516 — Interaction of Volatile Anesthetics With Magnesium · Phase 4 · recruiting
- NCT03497923 — Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block · Phase 4 · completed
- NCT03256955 — Validation of the TOF Cuff Monitor® Which Measures Neuromuscular Block on the Upper Arm · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03649672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Christoph Czarnetzki
- Last refreshed: 21 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03649672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing